The affordability of newly approved innovative health technologies (IHTs) is a significant challenge for many European health systems. So far, discussions have mostly focused on traditional issues like cost-effectiveness, quality of care and patient involvement, with limited success. ASCERTAIN addresses this by developing a Policy Support Tool. The tool covers new pricing models, a comprehensive health technology assessment (HTA) framework including cost-effectiveness and budget impact calculations, and new reimbursement and payment schemes. The ASCERTAIN framework is based on a review and analysis of existing pricing, thresholds, reimbursement models, and HTA frameworks, helping to define necessary elements for developing new models. New pricing models aim to balance improving patient access and encouraging entrepreneurship. Additionally, dynamic HTA models that consider the entire life cycle of health technologies include clinical cost-effectiveness, and budget impact aspects, allowing for updates when there are changes in indications or new comparators. The results from these models inform new reimbursement models and payment schemes. Recognising that affordability varies across EU member states, new methods to define thresholds were developed. Finally, the Policy Support Tool will be publicly available, enabling stakeholders to configure scenarios, execute models, and interpret results in a transparent and user-friendly manner.